Spyre Therapeutics (SYRE) stock: insider trades, news & valuation
Heavy selling
Close · Oct 9, 2026
$85.69
+7.2% on the day
+304.8% over 12 months
52-week range $18.91 – $108.92
Share price and insider trades
SYRE closeInsider buyInsider sale
Bought, 12 months$0
Sold, 12 months$443M
Insiders buying0
Insiders selling7
Spyre Therapeutics insider trading at a glance (Oct 9, 2026): in the past 12 months, 0 insiders bought $0 and 7 sold $443M of SYRE stock on the open market.
Get emailed when insiders cluster-buy stocks like SYRE
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
SYRE insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | $4.7M | 16 |
| Q3 2026 | — | 0 | $14.9M | 33 |
| Q2 2026 | — | 0 | $420M | 34 |
| Q1 2026 | — | 0 | $1.7M | 9 |
| Q4 2025 | — | 0 | $1.5M | 4 |
Valuation, profit and volume
P/E (trailing)n/aSector median —
Market value—
Profit margin—Revenue growth —
Volume vs. 50-day2.0×Last 5 sessions
Insiders' paper profit—On all tracked purchases —
Summary
Over the past 12 months, 0 Spyre Therapeutics, Inc. insiders reported open-market purchases totaling $0, while 7 insiders reported sales totaling $443M. 93 of 96 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Oct 2SEC | Scott L BurrowsCFO | Sell Plan | 17,50079,762 held (−18%) | $89.89 | $1.6M | -4.7% | — |
| Oct 2SEC | Heidy King-jonesSee Remarks | Sell Plan | 16,60514,773 held (−53%) | $90.35 | $1.5M | -5.2% | — |
| Oct 2SEC | Heidy King-jonesSee Remarks | Sell Plan | 7,2287,545 held (−49%) | $91.35 | $660K | -6.2% | — |
| Oct 2SEC | Cameron TurtleCEO | Sell Plan | 4,990537,640 held (−1%) | $93.37 | $466K | -8.2% | — |
| Oct 2SEC | Cameron TurtleCEO | Sell Plan | 3,989542,630 held (−1%) | $92.31 | $368K | -7.2% | — |
| Oct 2SEC | Scott L BurrowsCFO | Sell Plan | 3,07179,991 held (−4%) | $92.95 | $285K | -7.8% | — |
| Oct 2SEC | Heidy King-jonesSee Remarks | Sell Plan | 2,6002,845 held (−48%) | $93.46 | $243K | -8.3% | — |
| Oct 2SEC | Cameron TurtleCEO | Sell Plan | 2,683549,257 held (−0%) | $90.10 | $242K | -4.9% | — |
| Oct 2SEC | Cameron TurtleCEO | Sell Plan | 2,638546,619 held (−0%) | $91.49 | $241K | -6.3% | — |
| Oct 2SEC | Heidy King-jonesSee Remarks | Sell Plan | 2,1005,445 held (−28%) | $92.70 | $195K | -7.6% | — |
| Oct 2SEC | Scott L BurrowsCFO | Sell Plan | 2,10083,062 held (−2%) | $91.92 | $193K | -6.8% | — |
| Oct 2SEC | Scott L BurrowsCFO | Sell Plan | 1,50085,162 held (−2%) | $90.27 | $135K | -5.1% | — |
| Oct 2SEC | Cameron TurtleCEO | Sell Plan | 600551,940 held (−0%) | $89.14 | $53K | -3.9% | — |
| Oct 2SEC | Scott L BurrowsCFO | Sell Plan | 60086,662 held (−1%) | $89.07 | $53K | -3.8% | — |
| Oct 2SEC | Heidy King-jonesSee Remarks | Sell Plan | 40031,378 held (−1%) | $89.24 | $36K | -4.0% | — |
| Oct 2SEC | Scott L BurrowsCFO | Sell Plan | 22979,762 held (−0%) | $93.57 | $21K | -8.4% | — |
| Oct 2SEC | Cameron TurtleCEO | Sell Plan | 100537,540 held (−0%) | $93.91 | $9K | -8.8% | — |
| Sep 3SEC | Scott L BurrowsCFO | Sell Plan | 18,23279,762 held (−19%) | $89.35 | $1.6M | -4.1% | — |
| Sep 3SEC | Heidy King-jonesSee Remarks | Sell Plan | 16,5489,451 held (−64%) | $87.20 | $1.4M | -1.7% | — |
| Sep 3SEC | Cameron TurtleCEO | Sell Plan | 8,400556,640 held (−1%) | $87.15 | $732K | -1.7% | — |
| Sep 3SEC | Heidy King-jonesSee Remarks | Sell Plan | 6,2063,245 held (−66%) | $88.17 | $547K | -2.8% | — |
| Sep 3SEC | Heidy King-jonesSee Remarks | Sell Plan | 4,84525,999 held (−16%) | $86.40 | $419K | -0.8% | — |
| Sep 3SEC | Scott L BurrowsCFO | Sell Plan | 4,384100,210 held (−4%) | $87.11 | $382K | -1.6% | — |
| Sep 3SEC | Cameron TurtleCEO | Sell Plan | 3,700552,940 held (−1%) | $88.06 | $326K | -2.7% | — |
| Sep 3SEC | Cameron TurtleCEO | Sell Plan | 2,500565,040 held (−0%) | $86.36 | $216K | -0.8% | — |
| Sep 3SEC | Scott L BurrowsCFO | Sell Plan | 2,01698,194 held (−2%) | $88.03 | $177K | -2.7% | — |
| Sep 3SEC | Scott L BurrowsCFO | Sell Plan | 900104,594 held (−1%) | $86.25 | $78K | -0.6% | — |
| Sep 3SEC | Heidy King-jonesSee Remarks | Sell Plan | 4002,845 held (−12%) | $90.00 | $36K | -4.8% | — |
| Sep 3SEC | Heidy King-jonesSee Remarks | Sell Plan | 4002,845 held (−12%) | $89.38 | $36K | -4.1% | — |
| Sep 3SEC | Cameron TurtleCEO | Sell Plan | 400552,540 held (−0%) | $89.07 | $36K | -3.8% | — |
| Sep 3SEC | Scott L BurrowsCFO | Sell Plan | 20097,994 held (−0%) | $89.04 | $18K | -3.8% | — |
| Aug 10SEC | Jeffrey W. AlbersDirector | Sell Plan | 10,0009,360 held (−52%) | $104.68 | $1.0M | -18.1% | — |
| Aug 10SEC | Jeffrey W. AlbersDirector | Sell Plan | 8,00019,360 held (−29%) | $104.38 | $835K | -17.9% | — |
| Aug 10SEC | Jeffrey W. AlbersDirector | Sell Plan | 5,000 | $104.47 | $522K | -18.0% | — |
| Aug 5SEC | Cameron TurtleCEO | Sell Plan | 7,157574,583 held (−1%) | $95.10 | $681K | -9.9% | — |
| Aug 5SEC | Cameron TurtleCEO | Sell Plan | 5,635568,948 held (−1%) | $95.93 | $541K | -10.7% | — |
| Aug 5SEC | Scott L BurrowsCFO | Sell Plan | 5,100100,394 held (−5%) | $95.21 | $486K | -10.0% | — |
| Aug 5SEC | Scott L BurrowsCFO | Sell Plan | 2,30098,094 held (−2%) | $96.30 | $221K | -11.0% | — |
| Aug 5SEC | Cameron TurtleCEO | Sell Plan | 1,392567,556 held (−0%) | $96.82 | $135K | -11.5% | — |
| Aug 5SEC | Cameron TurtleCEO | Sell Plan | 800581,740 held (−0%) | $93.97 | $75K | -8.8% | — |
| Aug 5SEC | Scott L BurrowsCFO | Sell Plan | 10097,994 held (−0%) | $97.10 | $10K | -11.8% | — |
| Aug 5SEC | Cameron TurtleCEO | Sell Plan | 16567,540 held (−0%) | $97.46 | $2K | -12.1% | — |
| Jul 2SEC | Cameron TurtleCEO | Sell Plan | 10,176587,364 held (−2%) | $87.44 | $890K | -2.0% | — |
| Jul 2SEC | Sheldon SloanChief Medical Officer | Sell Plan | 6,5001,834 held (−78%) | $87.52 | $569K | -2.1% | — |
| Jul 2SEC | Scott L BurrowsCFO | Sell Plan | 5,77599,719 held (−5%) | $87.55 | $506K | -2.1% | — |
| Jul 2SEC | Cameron TurtleCEO | Sell Plan | 4,234583,130 held (−1%) | $88.12 | $373K | -2.8% | — |
| Jul 2SEC | Sheldon SloanChief Medical Officer | Sell Plan | 1,834 | $88.34 | $162K | -3.0% | — |
| Jul 2SEC | Scott L BurrowsCFO | Sell Plan | 1,72597,994 held (−2%) | $88.37 | $152K | -3.0% | — |
| Jul 2SEC | Cameron TurtleCEO | Sell Plan | 590582,540 held (−0%) | $88.91 | $52K | -3.6% | — |
| Jun 26SEC | Scott L BurrowsCFO | Sell | 10,00097,994 held (−9%) | $87.14 | $871K | -1.7% | — |
| Jun 26SEC | Scott L BurrowsCFO | Sell | 5,000107,994 held (−4%) | $87.12 | $436K | -1.6% | — |
| Jun 23SEC | Fairmount Funds Management LlcDirector | Sell | 4,684,781 | $85.31 | $400M | +0.4% | — |
| Jun 23SEC | Michael Thomas HendersonDirector | Sell Plan | 20,00068,606 held (−23%) | $100.00 | $2.0M | -14.3% | — |
| Jun 3SEC | Sheldon SloanChief Medical Officer | Sell Plan | 8,333 | $75.00 | $625K | +14.3% | — |
| Jun 3SEC | Cameron TurtleCEO | Sell Plan | 8,149600,834 held (−1%) | $70.50 | $575K | +21.5% | — |
| Jun 3SEC | Cameron TurtleCEO | Sell Plan | 3,557608,983 held (−1%) | $69.40 | $247K | +23.5% | — |
| Jun 3SEC | Cameron TurtleCEO | Sell Plan | 3,294597,540 held (−1%) | $71.38 | $235K | +20.0% | — |
| Jun 3SEC | Scott L BurrowsCFO | Sell Plan | 3,10097,994 held (−3%) | $72.06 | $223K | +18.9% | — |
| Jun 3SEC | Scott L BurrowsCFO | Sell Plan | 2,599101,094 held (−3%) | $70.77 | $184K | +21.1% | — |
| Jun 3SEC | Scott L BurrowsCFO | Sell Plan | 1,801103,693 held (−2%) | $69.75 | $126K | +22.9% | — |
| May 8SEC | Michael Thomas HendersonDirector | Sell Plan | 33,513132,689 held (−20%) | $73.72 | $2.5M | +16.2% | — |
| May 8SEC | Michael Thomas HendersonDirector | Sell Plan | 24,814107,875 held (−19%) | $74.76 | $1.9M | +14.6% | — |
| May 8SEC | Michael Thomas HendersonDirector | Sell Plan | 19,26988,606 held (−18%) | $75.35 | $1.5M | +13.7% | — |
| May 8SEC | Michael Thomas HendersonDirector | Sell Plan | 2,404166,202 held (−1%) | $72.57 | $174K | +18.1% | — |
| May 1SEC | Sheldon SloanChief Medical Officer | Sell Plan | 21,30657,027 held (−27%) | $69.53 | $1.5M | +23.2% | — |
| May 1SEC | Sheldon SloanChief Medical Officer | Sell Plan | 19,65637,371 held (−34%) | $70.61 | $1.4M | +21.4% | — |
| May 1SEC | Sheldon SloanChief Medical Officer | Sell Plan | 12,77715,817 held (−45%) | $72.94 | $932K | +17.5% | — |
| May 1SEC | Scott L BurrowsCFO | Sell Plan | 12,50097,994 held (−11%) | $71.37 | $892K | +20.1% | — |
| May 1SEC | Sheldon SloanChief Medical Officer | Sell Plan | 10,3585,459 held (−65%) | $73.74 | $764K | +16.2% | — |
| May 1SEC | Sheldon SloanChief Medical Officer | Sell Plan | 8,77728,594 held (−23%) | $71.56 | $628K | +19.7% | — |
| May 1SEC | Sheldon SloanChief Medical Officer | Sell Plan | 5,059400 held (−93%) | $74.60 | $377K | +14.9% | — |
| May 1SEC | Cameron TurtleCEO | Sell Plan | 5,300622,240 held (−1%) | $69.54 | $369K | +23.2% | — |
| May 1SEC | Cameron TurtleCEO | Sell Plan | 3,600618,640 held (−1%) | $70.77 | $255K | +21.1% | — |
| May 1SEC | Cameron TurtleCEO | Sell Plan | 3,100614,540 held (−1%) | $73.14 | $227K | +17.2% | — |
| May 1SEC | Cameron TurtleCEO | Sell Plan | 1,700612,840 held (−0%) | $74.23 | $126K | +15.4% | — |
| May 1SEC | Cameron TurtleCEO | Sell Plan | 1,000617,640 held (−0%) | $71.76 | $72K | +19.4% | — |
| May 1SEC | Sheldon SloanChief Medical Officer | Sell Plan | 400 | $75.37 | $30K | +13.7% | — |
| May 1SEC | Cameron TurtleCEO | Sell Plan | 300612,540 held (−0%) | $74.96 | $22K | +14.3% | — |
| Apr 3SEC | Cameron TurtleCEO | Sell Plan | 12,344630,196 held (−2%) | $49.20 | $607K | +74.2% | — |
| Apr 3SEC | Sheldon SloanChief Medical Officer | Sell Plan | 7,958 | $50.00 | $398K | +71.4% | — |
| Apr 3SEC | Scott L BurrowsCFO | Sell Plan | 6,20099,294 held (−6%) | $49.21 | $305K | +74.1% | — |
| Apr 3SEC | Cameron TurtleCEO | Sell Plan | 2,656627,540 held (−0%) | $49.92 | $133K | +71.7% | — |
| Apr 3SEC | Scott L BurrowsCFO | Sell Plan | 1,30097,994 held (−1%) | $49.98 | $65K | +71.4% | — |
| Mar 3SEC | Cameron TurtleCEO | Sell Plan | 9,100642,540 held (−1%) | $42.49 | $387K | +101.7% | — |
| Mar 3SEC | Cameron TurtleCEO | Sell Plan | 5,900651,640 held (−1%) | $41.73 | $246K | +105.3% | — |
| Mar 3SEC | Scott L BurrowsCFO | Sell Plan | 2,30098,194 held (−2%) | $40.56 | $93K | +111.3% | — |
| Mar 3SEC | Scott L BurrowsCFO | Sell Plan | 20097,994 held (−0%) | $41.66 | $8K | +105.7% | — |
| Feb 4SEC | Cameron TurtleCEO | Sell Plan | 14,043657,540 held (−2%) | $32.87 | $462K | +160.7% | — |
| Feb 4SEC | Cameron TurtleCEO | Sell Plan | 957671,583 held (−0%) | $31.82 | $30K | +169.3% | — |
| Jan 6SEC | Cameron TurtleCEO | Sell Plan | 12,709674,198 held (−2%) | $30.47 | $387K | +181.2% | — |
| Jan 6SEC | Cameron TurtleCEO | Sell Plan | 2,191672,007 held (−0%) | $31.79 | $70K | +169.6% | — |
| Jan 6SEC | Cameron TurtleCEO | Sell Plan | 100671,907 held (−0%) | $32.39 | $3K | +164.6% | — |
| Dec 3SEC | Cameron TurtleCEO | Sell Plan | 10,995690,912 held (−2%) | $28.73 | $316K | +198.3% | — |
| Dec 3SEC | Cameron TurtleCEO | Sell Plan | 4,005686,907 held (−1%) | $29.83 | $119K | +187.3% | — |
| Nov 5SEC | Cameron TurtleCEO | Sell Plan | 28,155718,752 held (−4%) | $23.13 | $651K | +270.5% | — |
| Nov 5SEC | Cameron TurtleCEO | Sell Plan | 16,845701,907 held (−2%) | $23.66 | $399K | +262.2% | — |
Insiders at Spyre Therapeutics, Inc.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Fairmount Funds Management LlcDirector | — | $400M | Jun 23, 2026 | — |
| Cameron TurtleCEO | — | $11.4M | Oct 2, 2026 | — |
| Scott L BurrowsCFO | — | $9.1M | Oct 2, 2026 | — |
| Michael Thomas HendersonDirector | — | $8.0M | Jun 23, 2026 | — |
| Sheldon SloanChief Medical Officer | — | $7.4M | Jul 2, 2026 | — |
| Heidy King-jonesSee Remarks | — | $5.1M | Oct 2, 2026 | — |
| Jeffrey W. AlbersDirector | — | $2.4M | Aug 10, 2026 | — |
SYRE stock: common questions
Are Spyre Therapeutics, Inc. insiders buying SYRE stock?
In the past 12 months, 0 insiders reported open-market purchases of SYRE worth $0.
Are Spyre Therapeutics, Inc. insiders selling SYRE stock?
7 insiders reported sales worth $443M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is SYRE's 52-week range?
Over the past year SYRE has traded between $18.91 and $108.92. It last closed at $85.69 on Oct 9, 2026.